Search clinical trials for: Immune checkpoint inhibitor (ICI)

Total 5118 results

Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Chondrosarcoma

China
Shanghai Pulmonary Hospital, Shanghai, China

Active, not recruiting

CX3CR1+T Cell Predict Immunotherapy Efficacy

Non-small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
First Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital... and other collaborators

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy (HNC-SYSU-003)

Radiotherapy | HNSCC | PD-1

China
Hunan Province Tumor Hospital

Recruiting

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer (ATHENA)

Non-small Cell Lung Cancer

China
Jounce Therapeutics, Inc.

Completed

Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies

Cancer

United States
First Affiliated Hospital of Zhejiang University

Unknown

Treatment of PD-1 Inhibitor in AIDS-associated PML (TPAP)

Progressive Multifocal Leukoencephalopathy | AIDS

China
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Italy, Spain, Turkey, Russian Federation, Ukraine, Israel, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Maastricht University Medical Center
Erasmus Medical Center; Jules Bordet Institute; Academisch Ziekenhuis Maastricht

Recruiting

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Unspecified Adult Solid Tumor, Protocol Specific

Netherlands, Belgium
Sun Yat-sen University

Recruiting

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients

Anal Canal Cancer | Anal Squamous Cell Carcinoma | Anal Cancer | Anal Canal Cancer Stage III

China
BioAtla, Inc.

Recruiting

A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma of the Head and Neck

United States
Genentech, Inc.

Recruiting

An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Korea, Republic of, Netherlands, Spain, United States, Brazil, Canada, Italy, Australia, Belgium
Shandong University
Chinese PLA General Hospital

Not yet recruiting

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Triple Negative Breast Cancer | Sensitivity | Neoadjuvant Immunotherapy
Bristol-Myers Squibb
Agenus Inc.

Active, not recruiting

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

Advanced Cancer

United States
Teon Therapeutics, Inc.
Merck Sharp & Dohme LLC

Terminated

TT-816 as Monotherapy or in Combination With a PD-1 Inhibitor in Patients With Advanced Cancers (SEABEAM) (MK3475-E88)

Cancer | Advanced Solid Tumor | Advanced Cancer | Oncology

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

China
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Merkel Cell Carcinoma | Cutaneous Melanoma | Cutaneous Squamous Cell Carcinoma

United States
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma

Soft Tissue Sarcoma

China
BioAtla, Inc.

Recruiting

CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

Melanoma | Head and Neck Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Well-differentiated Non-functional NET of Thoracic Origin | Well-differentiated Non-functional NET of Gastrointestinal Origin | Well-differentiated Non-functional NET of Pancreatic Origin | Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

United States, Italy, Spain, Japan, Belgium, Netherlands, Germany, France, Canada, Austria, United Kingdom, Australia
Asan Medical Center

Unknown

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Cancer | Lung Cancer Metastatic | Immunotherapy

Korea, Republic of
Texas Tech University Health Sciences Center

Not yet recruiting

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers (LOGIC)

Triple Negative Breast Cancer
Guangxi Medical University
Wuzhou Red Cross Hospital; Wuhan Union Hospital, China; Yunnan Cancer Hospital; Hainan People's Hospital and other collaborators

Not yet recruiting

PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Neoadjuvant Therapy | PD-1 Inhibitor
Second Affiliated Hospital of Soochow University

Recruiting

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Advanced Refractory Solid Tumors

China
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma

United States, Hong Kong, Taiwan
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Oral Squamous Cell Carcinoma | Anti-PD-1 | Neoadjvant Therapy | Anti-VEGFR

China
Canadian Cancer Trials Group
Melanoma and Skin Cancer Trials Limited

Recruiting

Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)

Unresectable/Metastatic Melanoma

Canada, Australia
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Non-Small-Cell Lung Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
Peking University Third Hospital

Not yet recruiting

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors (SCARCE)

Advanced Solid Tumor | Efficacy | Safety | Stereotactic Body Radiotherapy | Immune Checkpoint Inhibitor

China
Peking University First Hospital

Recruiting

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Urinary Bladder Cancer | Bladder Cancer | Bladder Neoplasms | Bladder Tumors | Neoplasms, Bladder

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer (PICARES)

Extensive-stage Small Cell Lung Cancer | Radiotherapy | Immunotherapy

China
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Tongji Hospital

Recruiting

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Hepatocellular Carcinoma | Effects of Immunotherapy | Programmed Cell Death 1

China
Fudan University

Recruiting

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

Nasopharyngeal Carcinoma

China
Second Affiliated Hospital of Soochow University

Not yet recruiting

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Metastatic Solid Tumor
Anhui Provincial Hospital

Not yet recruiting

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Esophageal Carcinoma
Novartis Pharmaceuticals

Completed

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

Hepatocellular Carcinoma (HCC) | Solid Malignancies

United States, Germany, Taiwan, Spain, Singapore, France, Japan, Korea, Republic of, Hong Kong, China, Italy
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Completed

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (SECOMBIT)

Metastatic Melanoma

Italy, Germany, Spain, Greece, Austria, France, Poland, Sweden, Switzerland, United Kingdom
Chinese PLA General Hospital

Recruiting

Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy

Gastric Cancer | Chemotherapy | Immunotherapy | Tumor Microenvironment

China
Fudan University

Not yet recruiting

Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer (PTCA199-8)

Pancreatic Cancer
Henan Cancer Hospital

Active, not recruiting

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

HER2 Positive Metastatic Breast Cancer

China
NovoCure GmbH

Active, not recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NSCLC | Nonsmall Cell Lung Cancer

United States, Poland, Hong Kong, China, Spain, Serbia, Croatia, France, Canada, Netherlands, Austria, Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Switzerland
University Hospital, Caen

Unknown

Immune Checkpoint Inhibitors Rechallenge After Immune-related Adverse Events (19-916)

Cancer

France

Search clinical trials for: Immune checkpoint inhibitor (ICI)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations